Trials Sponsors Conditions Drugs Pricing

Conditions

Brain Metastases

Keywords

Magnetic Resonance Imaging-guided Adaptive Radiotherapy

Outcome Measures

Primary Outcomes (1)

Intra-cranial progression-free survival (IPFS)
Defined as the time from date of radiation until the date of first documented intracalcarine recurrence or progression, or date of death from any cause, whichever came first.
From the date of radiation until the date of first documented intracalcarine recurrence or progression, or date of death from any cause, whichever came first, assessed up to 12 months.

Secondary Outcomes (5)

Local control rate (LCR)
Tumor assessment using RECIST will be performed at baseline then every 3 months from first treatment until objective progression or death from any cause, assessed up to 12 months.
Overall survival (OS)
From the date of radiation until the date of any documented death due to any cause,, assessed up to 12 months.
Objective Response Rate (ORR)
Tumor assessment using RECIST will be performed at baseline then every 3 months from first treatment until objective progression or death from any cause, assessed up to 12 months.
Disease control rate (DCR)
Tumor assessment using RECIST will be performed at baseline then every 3 months from first treatment until objective progression or death from any cause, assessed up to 12 months.
Adverse Event
AEs and SAEs must be collected from the start of treatment to 28 days after discontinuation of radiation, up to 12 months.

Study Arms (1)

BM patients receiving MRIgART

For it's an observational study, all patients eligible will be divided into the group "BM patients receiving MRIgART"

Radiation: magnetic resonance imaging-guided adaptive radiotherapy

Interventions

magnetic resonance imaging-guided adaptive radiotherapyRadiation

Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)

BM patients receiving MRIgART

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients from Cancer Institute and Hospital, Chinese Academy of Medical Sciences

You may qualify if:

Age ≥ 18 years; KPS score ≥ 60.

Sponsors & Collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Otherlead

Study Sites (1)

Chinese Academy of Medical Science and Peking Union Medical College

Beijing, China

RECRUITING

Nan Bi, MD, PhDCONTACT+861087788799 binan_email@163.com

MeSH Terms

Conditions

Brain Neoplasms

Condition Hierarchy (Ancestors)

Central Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

Nan Bi, MD
Chinese Academy of Medical Sciences and Peking Union Medical College
PRINCIPAL INVESTIGATOR

Central Study Contacts

Nan Bi, MD

CONTACT

8601087788799 binan_email@163.com

Yuchao Ma, MD

CONTACT

mycbyts@126.com

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: OTHER
Target Duration: 1 Year
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

May 4, 2024

First Posted

May 8, 2024

Study Start

January 3, 2020

Actual (reported)

Primary Completion

March 18, 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (1)

BM patients receiving MRIgART

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (1)

BM patients receiving MRIgART

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations